Leerink Partners Reiterates Market Perform Rating on Halozyme Therapeutics (HALO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®
October 3, 2024 8:00 AM EDTFour new targets nominated for total of six nominated targets, including FcRn (VYVGART® Hytrulo), for ENHANZE® drug delivery technology
Halozyme to receive total upfront payment of $30 million for exclusive rights to targets
SAN DIEGO, Oct. 3, 2024 /PRNewswire/ --Â Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that argenx has nominated four new... More
